Efineptakin alfa

Summary

Efineptakin alfa (NT-I7, rhIL-7-hyFc) is a long-acting recombinant human IL-7 fused to a hybrid Fc domain, developed by NeoImmuneTech. It is under investigation for treating lymphopenia, enhancing immune reconstitution, and augmenting anti-tumor immune responses, particularly in combination with checkpoint inhibitors and as an adjunct in COVID-19 and cancer immunotherapy.

Mechanism of Action

Recombinant human IL-7 analog that binds IL-7 receptor (IL-7Rα/CD127) on T lymphocytes, promoting T-cell survival, proliferation, and differentiation. Enhances thymopoiesis and peripheral T-cell expansion, restoring immune function in lymphopenic or immunocompromised states.

Routes of Administration

Goals & Uses

• HIV-associated immune deficiencyInfectious Disease / ImmunologyLow
• Sepsis-induced immunosuppressionCritical Care / ImmunologyLow
• Glioblastoma multiforme (GBM)OncologyLow
• Cancer immunotherapy augmentationOncologyModerate
• Immune reconstitution in lymphopeniaImmunologyModerate
• COVID-19 lymphopenia treatmentInfectious DiseaseModerate

Contraindications

• Known hypersensitivity to efineptakin alfa or componentsAllergy/HypersensitivityHigh
• Organ transplant recipients on immunosuppressionTransplantHigh
• Lymphoma or other T-cell malignanciesOncologyHigh
• Active autoimmune diseaseAutoimmunityHigh

Adverse Effects

• Injection site reactionsLocalCommon
• Skin rash / urticariaDermatologicalUncommon
• Flu-like symptoms / systemic reactionsSystemicCommon
• Transient eosinophiliaHematologicalCommon
• SplenomegalyHematologicUncommon
• LymphadenopathyLymphoreticularUncommon

Drug Interactions

• Systemic corticosteroidsModerate
• Cytotoxic chemotherapyModerate
• Immunosuppressive agents (e.g., tacrolimus, cyclosporine)High
• Anti-PD-1/PD-L1 checkpoint inhibitors (e.g., pembrolizumab, nivolumab)Low

Population Constraints

• Severe hepatic or renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Patients with active malignant T-cell disordersOncologicalAbsolute

Regulatory Status

• European UnionInvestigationalUnder clinical investigation; no EMA marketing authorization.
• United StatesInvestigationalFDA Fast Track designation for multiple oncology indications including GBM. Multiple active IND-supported Phase I/II trials.
• United KingdomInvestigationalNo MHRA approval; investigational use only.

Granted Fast Track designation by the US FDA for multiple oncology indications. Not yet approved in any jurisdiction; multiple Phase I/II clinical trials ongoing globally.

Evidence & Sources

No sources recorded yet.